Accuray vs MiMedx Group
MiMedx Group reported revenue of $419 million in fiscal 2025, about the same as Accuray's $402 million in fiscal 2026. Accuray's revenue fell 12.3% in its latest year, and MiMedx Group's grew 20.0%. Accuray had an operating margin of -6.6%, against 15.3% at MiMedx Group. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| Accuray | MiMedx Group | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $402M | $419M |
| Revenue growth | −12.3% | 20.0% |
| Revenue growth a year, last 5 years | 0.3% | 11.0% |
| Gross margin | 27.7% | 82.6% |
| Operating margin | −6.6% | 15.3% |
| Net margin | −12.2% | 11.6% |
| Free cash flow | −$13M | — |
| Free cash flow margin | −3.2% | — |
| Return on capital | — | 43.3% |
| Net debt to EBITDA | — | −1.9x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 19.3% | 0.5% |
| Last close | $2.12 | $3.11 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $134,146, sold $0 | — |
| Piotroski F-score | — | 7 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AccurayMiMedx Group
Operating margin
Percent of revenue
AccurayMiMedx Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AccurayMiMedx Group
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Accuray and MiMedx Group pages.